NICE not recommending teduglutide for SBS

NICE not recommending teduglutide for SBS PharmacoEconomics & Outcomes News 792, p34 - 2 Dec 2017 NICE not recommending teduglutide for SBS In draft guidance, the UK National Institute for Health and Care Excellence (NICE) has not recommended teduglutide (Revestive) for the treatment of short bowel syndrome (SBS) within the NHS, reported Selina McKee in PharmaTimes. NICE’s appraisal committee found that although teduglutide reduces the requirement for intravenous nutrition in patients with short bowel syndrome, it does not eliminate the need. Moreover, the estimated incremental cost- effectiveness ratio for teduglutide was £193 549 per QALY gained in adults, which exceeded NICE’s willingness-to-pay threshold for NHS funding. * National Health Service McKee S. NICE turns down Shire’s Revestive for bowel condition Pharma Times : 14 Nov 2017. Available from: URL: http://www.pharmatimes.com/news/ nice_turns_down_shires_revestive_for_bowel_condition_1211408 803283335 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

NICE not recommending teduglutide for SBS

Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/nice-not-recommending-teduglutide-for-sbs-oWXt1MAiz6
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
D.O.I.
10.1007/s40274-017-4557-8
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 792, p34 - 2 Dec 2017 NICE not recommending teduglutide for SBS In draft guidance, the UK National Institute for Health and Care Excellence (NICE) has not recommended teduglutide (Revestive) for the treatment of short bowel syndrome (SBS) within the NHS, reported Selina McKee in PharmaTimes. NICE’s appraisal committee found that although teduglutide reduces the requirement for intravenous nutrition in patients with short bowel syndrome, it does not eliminate the need. Moreover, the estimated incremental cost- effectiveness ratio for teduglutide was £193 549 per QALY gained in adults, which exceeded NICE’s willingness-to-pay threshold for NHS funding. * National Health Service McKee S. NICE turns down Shire’s Revestive for bowel condition Pharma Times : 14 Nov 2017. Available from: URL: http://www.pharmatimes.com/news/ nice_turns_down_shires_revestive_for_bowel_condition_1211408 803283335 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792

Journal

PharmacoEconomics & Outcomes NewsSpringer Journals

Published: Dec 2, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from Google Scholar, PubMed
Create lists to organize your research
Export lists, citations
Read DeepDyve articles
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off